Atezolizumab combo in first-line NSCLC misses cost-effectiveness markJuly 16, 2019Lung CancerPractice Management
Multigene panel sequencing is moderately cost-effective in NSCLCJuly 1, 2019Lung CancerPractice Management
FDA approves bevacizumab-bvzr for several cancersJune 28, 2019Gynecologic CancerRenal Cell CarcinomaLung CancerGastroenterologyGenitourinary CancerCNS/Brain CancerNeuro-oncology
Immunotherapy-treated NSCLC: Adverse impact of steroids driven by palliative indicationsJune 24, 2019Lung CancerPatient & Survivor Care
Adding ipilimumab to nivolumab provides no benefit in SCC trialJune 12, 2019Lung CancerImmuno-oncology
Adjuvant immunotherapy results ‘encouraging’ in early NSCLCJune 11, 2019Lung CancerImmunotherapyImmuno-oncology
